Yüklüyor......
Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case...
Kaydedildi:
| Yayımlandı: | Mol Clin Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7783712/ https://ncbi.nlm.nih.gov/pubmed/33414911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2192 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|